Zoetis Inc. ZTS
83.82 USD +0.86 (+1.04%)
Regular-session close
84.47 +0.65 +0.78%
Pre-market · Nov 16, 5:41 AM ET
82.27 Day range 83.85
68.77 52-week range 132.49
- YTD
- -33.38%
- 1 year
- -30.82%
News
defenseworld.net Zoetis Inc. $ZTS Shares Sold by Commonwealth Equity Services LLC Commonwealth Equity Services LLC lowered its stake in Zoetis Inc. (NYSE: ZTS) by 24.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission…
zacks.com Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
seekingalpha.com SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026 The 4-Factor Dividend Growth Strategy targets quality and total return, outperforming SCHD with a 14.98% average return versus SCHD's 14.31%. I select stocks based on free cash flow to debt, 5-year…
businesswire.com Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
businesswire.com Zoetis to Participate in the Jefferies Global Healthcare Conference in London PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a…
zacks.com ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
benzinga.com Republican Senator Who Won Reelection Is Selling Magnificent Seven Stocks: Here Are the Trades Sen. Shelley Moore Capito, who won reelection, sold shares of Apple, Meta and Microsoft weeks before the midterms. Here are the trades.
benzinga.com Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy Zoetis beats Q3 earnings and revenue estimates, lifts full-year 2026 guidance, and balances pet care affordability pressures with steady livestock gains.
benzinga.com Zoetis Q3 2026 Earnings Call Transcript Zoetis (NYSE:ZTS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Zoetis Raises FY2026 Adj EPS Guidance from $6.15-$6.25 to $6.25-$6.35 vs $6.28 Est; Raises FY2026 Sales Guidance from $9.120B-$9.320B to $9.220B-$9.320B vs $9.326B Est Zoetis (NYSE:ZTS) raises FY2026 Adj EPS guidance from $6.15-$6.25 to $6.25-$6.35 vs $6.28 analyst estimate. Raises FY2026 sales outlook from $9.120 billion-$9.320 billion to $9.220 billion-$9.320…
benzinga.com Zoetis Q3 Adj. EPS $1.75 Beats $1.51 Estimate, Sales $2.391B Beat $2.304B Estimate Zoetis (NYSE:ZTS) reported quarterly earnings of $1.75 per share which beat the analyst consensus estimate of $1.51 by 15.89 percent. This is a 2.94 percent increase over earnings of $1.70 per share…
benzinga.com Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $82 Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $85 to $82.
benzinga.com UBS Maintains Neutral on Zoetis, Raises Price Target to $85 UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $80 to $85.
benzinga.com This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Werner, Zoetis, Apple, Heartland Express and Elanco, cutting ratings to Neutral/Hold and lowering price targets.benzinga.com Jefferies Downgrades Zoetis to Hold, Lowers Price Target to $83 Jefferies analyst Keith Devas downgrades Zoetis (NYSE:ZTS) from Buy to Hold and lowers the price target from $103 to $83.
benzinga.com Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74 Goldman Sachs analyst Matt Dellatorre initiates coverage on Zoetis (NYSE:ZTS) with a Neutral rating and announces Price Target of $74.
finance.yahoo.com Keel Infrastructure Corp. (KEEL) Latest Stock News & Headlines - Yahoo Finance KEEL is shifting from Bitcoin mining toward artificial intelligence and high-performance computing data centers. Recent coverage centers on delayed Pennsylvania permits, unsigned leases, and Moses ...
finance.sina.com.cn 【机构持仓】贝莱德增持硕腾 最新披露的机构持仓数据显示,贝莱德于最新季度调整了对硕腾(ZTS)的持仓。 主要变动如下: 持仓变化:增持11万股 仓位变化幅度:0.41% 最新持股:2710万股 占公司流通股比例:6.67% 截至目前,公司共有3407家机构持股。 其中: 前20大机构合计持股2亿股,占总股本49.23%。 较上一季度提升2.35个百分点,机构持仓集中度呈现提升趋势。…
finance.sina.com.cn 【机构持仓】范埃克联合公司增持硕腾 郑重声明:1.根据《证券法》规定,禁止编造、传播虚假信息或者误导性信息,扰乱证券市场;2.用户在本社区发表的所有资料、言论等仅代表个人观点,与本网站立场无关,不对您构成任何投资建议。用户应基于自己的独立判断,自行决定证券投资并承担相应风险。
ad-hoc-news.de Zoetis stock gains USDA license for 75-day itch treatment Zoetis stock gets a USDA license for Cytopoint Plus, a canine allergic-dermatitis treatment designed to last 75 days. The ...
msn.com Geplante Kapitalrente: So viel Geld könnte sie im Alter bringen Die Kapitalrente soll die Altersvorsorge um eine neue Säule ergänzen. Modellrechnungen zeigen, welche Beträge dabei nach ...
